Executive Summary
This digest covers $5.2 billion in contract option exercises, all from civilian agencies, with zero defense-related awards. The dominant signal is a massive $4.81B sole-source award to **Leidos Biomedical Research** from the Department of Health and Human Services, representing 93% of total obligation and carrying the highest conviction (bullish, 7/10).
This dwarfs two smaller, competitively-won civilian contracts to **Cardinal Intellectual Property** ($192M, USPTO) and **OptumServe** ($190M, VA). The key risk is the lack of defense exposure in a period typically sensitive to Continuing Resolution dynamics, while the key watch item is the activation status of the Leidos Biomedical contract, given its size and potential for revenue recognition delays.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Option Exercises digest from July 12, 2026.
Investment Signals (3)
- Leidos Biomedical Research Captures $4.81B HHS Award (HIGH)▲
Leidos Biomedical Research secured a $4.81B defense contract from HHS, a signal of deep competitive moat and likely sole-source or urgent-need award. This is the highest-conviction signal in the digest, with 7/10 strength and 8/10 materiality.
- OptumServe's $190M VA Contract Nears Full Execution (MEDIUM)▲
OptumServe's $190M VA disability exam contract is 92.4% outlayed, indicating strong cash flow realization and successful cost management under a firm-fixed-price structure. This confirms UnitedHealth Group's competitive position in VA health services.
- Cardinal Intellectual Property's $192M USPTO Contract Shows Zero Outlay (MEDIUM)▲
Despite a 13-year, $192M firm-fixed-price contract from the USPTO, Cardinal Intellectual Property has $0 outlayed, suggesting the contract may be inactive or in early stages. This poses execution risk and delays revenue recognition.
Risk Flags (3)
- Execution [HIGH RISK]▼
Leidos Biomedical's $4.81B HHS contract lacks revenue recognition data, creating uncertainty about activation and cash flow timing.
- Budget [MEDIUM RISK]▼
All three contracts are civilian (HHS, Commerce, VA), making them vulnerable to Continuing Resolution (CR) uncertainty if appropriations lapse. No defense contracts provide a buffer.
- Competition [MEDIUM RISK]▼
Cardinal Intellectual Property's $192M USPTO contract was awarded under full and open competition with no set-aside, meaning it faces recompetition risk at the 2025 end date.
Opportunities (2)
- ◆
Leidos Biomedical's $4.81B HHS award signals potential for further civilian agency expansion, particularly in health and biomedical research services.
- ◆
OptumServe's success in VA disability exams suggests UnitedHealth Group could expand into other VA or defense health services contracts, leveraging its competitive win.
Sector Themes (2)
- ◆
All three contracts ($5.2B total) are from civilian agencies (HHS, Commerce, VA), with zero defense-related awards. This contrasts with typical DOD-heavy procurement patterns and highlights civilian budget resilience.
- ◆
Two contracts (Cardinal Intellectual Property, OptumServe) are firm-fixed-price, transferring cost risk to contractors. OptumServe's 92.4% outlay rate shows successful execution, while Cardinal's $0 outlay raises concerns.
Watch List (3)
- 👁
{"entity"=>"Leidos Holdings (LDOS)", "reason"=>"The $4.81B HHS contract is the largest single award and lacks outlay data, making activation and revenue recognition critical.", "trigger"=>"First contract outlay report or financial disclosure"}
- 👁
{"entity"=>"Cardinal Intellectual Property Inc.", "reason"=>"The $192M USPTO contract has $0 outlayed, suggesting potential delays or inactivity.", "trigger"=>"Contract modification or outlay announcement"}
- 👁
{"entity"=>"UnitedHealth Group (UNH)", "reason"=>"OptumServe's VA contract is nearly fully executed, raising recompetition risk for future VA disability exam contracts.", "trigger"=>"New VA solicitation for Region 2 or similar services"}
Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Option Exercises
🇺🇸 More from United States
View all →July 13, 2026
US Pre-Market SEC Filings Roundup — July 13, 2026
US Pre-Market SEC Filings Roundup
July 13, 2026
S&P 500 Financials Sector SEC Filings — July 13, 2026
S&P 500 Financials Sector SEC Filings
July 13, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — July 13, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
July 13, 2026
Nasdaq 100 Stocks SEC Filings — July 13, 2026
Nasdaq 100 Stocks SEC Filings